A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis
Journal of the American Academy of Dermatology（2021）
Key words
Clinical trial,Cutaneous Dermatomyositis Disease Area and Severity Index,dermatomyositis,drug development,oligonucleotide antagonist,toll-like receptors,type I interferon signaling
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined